Bullish news on cancer research and a looming patent publish date ETA June 1st. Earnings suck but they're shedding debt notes maybe for a buyout? Heads up on breakouts (short sellers wet dream). Cups within cups within cups. Dunno, DYOR and not investment advice.
we have a shark pattern on the 2nd wave with a reversal point of $2.23 and on $2.1 C-1-2 could form the cypher pattern. so we have a reversal PRZ with two patterns and since the target of both two patterns is between $11 and $11.7 also we have a target PRZ. the candle of this week could be a beautiful reversal green hammer.
*Wait till the pattern completed and the candle confirmation*
if ABC cypher:
if ABC shark:
I used the cypher pattern with BC=1.42 AB scenario
bat pattern with 4-5=0.88 3-4
it tested 26 days moving average one time and now could break it and rise to 5 under 55 days moving average then pullback to 26 days moving average. after breaking cloud resistance on 7 could reach to 10 or 14
We can see here that ENZC has had alot of good moves recently, for both the bulls and the bears. However, lets have a look at the fibs and see what that tell us.....
Without news we can plan for a move to the 0.618 area @ 0.59 . That would be a 0.12 cent move, awesome news! Thats over a 20% gain from its current price. With news however, this stock could easily...
* This is not financial advice. This is my non-expert opinion. *
Vistagen ( NASDAQ:VTGN ) is a clinical stage biopharmaceutical company with long-term potential. I believe it's technology is similarly game-changing the way I believe NanoFlu for Novavax is (www.novavax.com) ( ). It could have positive outcomes for the world. I hope...
NASDAQ:VTGN This isn't financial advice (hell no). I like this stock. The company has potential. This is a nice buying opportunity in non-expert opinion. So, I'm scooping up before their phase 3 trials.
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy...
One Medical presented at the JPM Healthcare Forum, and apparently wowed the attendees.
It's a COVID play.
It's IDB's Stock of the Day coincidentally.
As it broke out of the cup with a handle formation, the Ultimate Indicator flashes a BUY signal, with 8 confirmations.
It's a keeper.
Happy Trading, from CJ -- aka the greatest FURU.
To find out more about The...
La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe
La Jolla to receive upfront cash payment of $22.5 million plus potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments
Under the terms of the exclusive licensing agreement, La...
128M Market Cap can show good results in near future. Q3 2020 EPS results IS better compare to Q2 and Q1 2020. Reward can be better compare to Risk.
Institutional Buying also increased. Price can move 2 to 9 USD.
Curis Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Key findings include:
- Marrow blast reductions observed in all evaluable patients (6 patients).
- 6 of 7 patients enrolled remain on study.
- Patients enrolled experienced a...
Solid Biosciences Announces $90 Million Private Placement
Solid Biosciences has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $90 million private placement, which is expected to close on or about December 15, 2020, subject to the satisfaction of customary closing conditions.